|
1
|
Trayhurn P and Wood IS: Adipokines:
inflammation and the pleiotropic role of white adipose tissue. Br J
Nutr. 92:347–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wozniak SE, Gee LL, Wachtel MS and Frezza
EE: Adipose tissue: the new endocrine organ? A review article. Dig
Dis Sci. 54:1847–1856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kontny E, Plebanczyk M, Lisowska B, et al:
Comparison of rheumatoid articular adipose and synovial tissue
reactivity to proinflammatory stimuli: contribution to
adipocytokine network. Ann Rheum Dis. 71:262–267. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Gomez R, Conde J, Scotece M, et al: What’s
new in our understanding of the role of adipokines in rheumatic
diseases? Nat Rev Rheumatol. 7:528–536. 2011.
|
|
5
|
Neumann E, Frommer KW, Vasile M and
Müller-Ladner U: Adipocytokines as driving forces in rheumatoid
arthritis and related inflammatory diseases? Arthritis Rheum.
63:1159–1169. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ehling A, Schaffler A, Herfarth H, et al:
The potential of adiponectin in driving arthritis. J Immunol.
176:4468–4478. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kitahara K, Kusunoki N, Kakiuchi T, Suguro
T and Kawai S: Adiponectin stimulates IL-8 production by rheumatoid
synovial fibroblasts. Biochem Biophys Res Commun. 378:218–223.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Stofkova A: Leptin and adiponectin: from
energy and metabolic dysbalance to inflammation and autoimmunity.
Endocr Regul. 43:157–168. 2009.PubMed/NCBI
|
|
9
|
Luk T, Malam Z and Marshall JC: Pre-B cell
colony-enhancing factor (PBEF)/visfatin: a novel mediator of innate
immunity. J Leukoc Biol. 83:804–816. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brentano F, Schorr O, Ospelt C, et al:
Pre-B cell colony-enhancing factor/visfatin, a new marker of
inflammation in rheumatoid arthritis with proinflammatory and
matrix-degrading activities. Arthritis Rheum. 56:2829–2839. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bokarewa M, Nagaev I, Dahlberg L, Smith U
and Tarkowski A: Resistin, an adipokine with potent proinflammatory
properties. J Immunol. 174:5789–5795. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Arnett FC, Edworthy SM, Bloch DA, et al:
The American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum.
31:315–324. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Inoue E, Yamanaka H, Hara M, Tomatsu T and
Kamatani N: Comparison of Disease Activity Score (DAS)28-
erythrocyte sedimentation rate and DAS28- C-reactive protein
threshold values. Ann Rheum Dis. 66:407–409. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fries JF, Spitz P, Kraines RG and Holman
HR: Measurement of patient outcome in arthritis. Arthritis Rheum.
23:137–145. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Felson DT, Anderson JJ, Boers M, et al;
American College of Rheumatology. Preliminary definition of
improvement in rheumatoid arthritis. Arthritis Rheum. 38:727–735.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cansu B, Cansu DU, Kaşifoģlu T, Gülbas Z
and Korkmaz C: Disease-modifying antirheumatic drugs increase serum
adiponectin levels in patients with rheumatoid arthritis. J Clin
Rheumatol. 17:14–17. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lewicki M, Kotyla P and Kucharz E:
Etanercept increases adiponectin level in woman with rheumatoid
arthritis. Clin Rheumatol. 27:1337–1338. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Komai N, Morita Y, Sakuta T, Kuwabara A
and Kashihara N: Anti-tumor necrosis factor therapy increases serum
adiponectin levels with the improvement of endothelial dysfunction
in patients with rheumatoid arthritis. Mod Rheumatol. 17:385–390.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Popa C, Netea MG, de Graaf J, et al:
Circulating leptin and adiponectin concentrations during tumor
necrosis factor blockade in patients with active rheumatoid
arthritis. J Rheumatol. 36:724–730. 2009. View Article : Google Scholar
|
|
20
|
Gonzalez-Gay MA, Vazquez-Rodriguez TR,
Garcia-Unzueta MT, et al: Visfatin is not associated with
inflammation or metabolic syndrome in patients with severe
rheumatoid arthritis undergoing anti-TNF-alpha therapy. Clin Exp
Rheumatol. 28:56–62. 2010.PubMed/NCBI
|
|
21
|
Gonzalez-Gay MA, Garcia-Unzueta MT,
Gonzalez-Juanatey C, et al: Anti-TNF-alpha therapy modulates
resistin in patients with rheumatoid arthritis. Clin Exp Rheumatol.
26:311–316. 2008.PubMed/NCBI
|
|
22
|
Popa C, Netea MG, Radstake TR, et al:
Markers of inflammation are negatively correlated with serum leptin
in rheumatoid arthritis. Ann Rheum Dis. 64:1195–1198. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Presle N, Pottie P, Dumond H, et al:
Differential distribution of adipokines between serum and synovial
fluid in patients with osteoarthritis. Contribution of joint
tissues to their articular production. Osteoarthritis Cartilage.
14:690–695. 2006. View Article : Google Scholar
|
|
24
|
Senolt L, Pavelka K, Housa D and Haluzik
M: Increased adiponectin is negatively linked to the local
inflammatory process in patients with rheumatoid arthritis.
Cytokine. 35:247–252. 2006. View Article : Google Scholar
|
|
25
|
Neumeier M, Weigert J, Schäffler A, et al:
Different effects of adiponectin isoforms in human monocytic cells.
J Leukoc Biol. 79:803–808. 2006. View Article : Google Scholar : PubMed/NCBI
|
